163 related articles for article (PubMed ID: 35851797)
1. Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review.
Farkowski MM; Karlinski M; Pytkowski M; de Asmundis C; Lewandowski M; Mugnai G; Conte G; Marijon E; Anic A; Boveda S; Providencia R
Europace; 2022 Oct; 24(9):1504-1511. PubMed ID: 35851797
[TBL] [Abstract][Full Text] [Related]
2. Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study.
Mugnai G; Paolini C; Cavedon S; Mecenero A; Perrone C; Bilato C
Acta Cardiol; 2022 May; 77(3):264-270. PubMed ID: 34006205
[TBL] [Abstract][Full Text] [Related]
3. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
AbdelWahab A; Sapp J
Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
[TBL] [Abstract][Full Text] [Related]
4. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks.
Sobiech M; Lewandowski M; Zając D; Maciąg A; Syska P; Ateńska-Pawłowska J; Kowalik I; Sterliński M; Szwed H; Pytkowski M
Kardiol Pol; 2017; 75(10):1027-1032. PubMed ID: 29057449
[TBL] [Abstract][Full Text] [Related]
6. Dramatic reduction of ventricular tachycardia burden after dronedarone plus mexiletine treatment in a patient refractory to hybrid ablation.
Frutos-López M; Pedrote A; Acosta-Martínez J; Arana-Rueda E
Rev Port Cardiol (Engl Ed); 2020 Mar; 39(3):171-173. PubMed ID: 32336522
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials.
Santangeli P; Muser D; Maeda S; Filtz A; Zado ES; Frankel DS; Dixit S; Epstein AE; Callans DJ; Marchlinski FE
Heart Rhythm; 2016 Jul; 13(7):1552-9. PubMed ID: 26961297
[TBL] [Abstract][Full Text] [Related]
8. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator.
Gao D; Van Herendael H; Alshengeiti L; Dorian P; Mangat I; Korley V; Ahmad K; Golovchiner G; Aves T; Pinter A
J Cardiovasc Pharmacol; 2013 Aug; 62(2):199-204. PubMed ID: 23609328
[TBL] [Abstract][Full Text] [Related]
9. Oral mexiletine for ventricular tachyarrhythmias treatment in implantable cardioverter-defibrillator patients: a systematic review of the literature.
Ali H; Cristiano E; Lupo P; Foresti S; DE Ambroggi G; DE Lucia C; Turturiello D; Paganini EM; Bessi R; Farghaly AA; Nicolì L; Cappato R
Minerva Cardiol Angiol; 2023 Dec; 71(6):622-630. PubMed ID: 36305779
[TBL] [Abstract][Full Text] [Related]
10. Use of mexiletine in therapy-refractory recurrent ventricular tachycardia storm.
Szonyi MD; Pap R; Vamos M
Herzschrittmacherther Elektrophysiol; 2023 Dec; 34(4):326-329. PubMed ID: 37917362
[TBL] [Abstract][Full Text] [Related]
11. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
Sapp JL; Wells GA; Parkash R; Stevenson WG; Blier L; Sarrazin JF; Thibault B; Rivard L; Gula L; Leong-Sit P; Essebag V; Nery PB; Tung SK; Raymond JM; Sterns LD; Veenhuyzen GD; Healey JS; Redfearn D; Roux JF; Tang AS
N Engl J Med; 2016 Jul; 375(2):111-21. PubMed ID: 27149033
[TBL] [Abstract][Full Text] [Related]
12. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery.
Naccarella F; Rolli A; Carboni A; Finardi A; Aurier E; Favaro L; Contini S; Gherli T; Caponi D; Maranga SS; Lepera G; Bartoletti A
G Ital Cardiol; 1999 Oct; 29(10):1142-56. PubMed ID: 10546124
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kheiri B; Barbarawi M; Zayed Y; Hicks M; Osman M; Rashdan L; Kyi HH; Bachuwa G; Hassan M; Stecker EC; Nazer B; Bhatt DL
Circ Arrhythm Electrophysiol; 2019 Nov; 12(11):e007600. PubMed ID: 31698933
[TBL] [Abstract][Full Text] [Related]
14. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest: a critical review of the Antiarrhythmics Versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator Study.
Farré J; Cabrera JA; Romero J; Rubio JM
Am J Cardiol; 2000 Nov; 86(9A):44K-51K. PubMed ID: 11084100
[TBL] [Abstract][Full Text] [Related]
16. Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy.
Samuel M; Healey JS; Nault I; Sterns LD; Essebag V; Gray C; Hruczkowski T; Gardner M; Parkash R; Sapp JL
JACC Clin Electrophysiol; 2023 Jun; 9(6):808-821. PubMed ID: 37380314
[TBL] [Abstract][Full Text] [Related]
17. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
[TBL] [Abstract][Full Text] [Related]
18. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
Arenal Á; Ávila P; Jiménez-Candil J; Tercedor L; Calvo D; Arribas F; Fernández-Portales J; Merino JL; Hernández-Madrid A; Fernández-Avilés FJ; Berruezo A
J Am Coll Cardiol; 2022 Apr; 79(15):1441-1453. PubMed ID: 35422240
[TBL] [Abstract][Full Text] [Related]
19. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
Connolly SJ; Gent M; Roberts RS; Dorian P; Roy D; Sheldon RS; Mitchell LB; Green MS; Klein GJ; O'Brien B
Circulation; 2000 Mar; 101(11):1297-302. PubMed ID: 10725290
[TBL] [Abstract][Full Text] [Related]
20. Japanese randomized trial for investigation of a combined therapy of amiodarone and implantable cardioverter defibrillator in patients with ventricular tachycardia and fibrillation: the Nippon ICD Plus Pharmachologic Option Necessity study design.
Kurita T; Mitamura H; Aizawa Y; Nitta T; Aonuma K; Tsuboi N; Chinushi M; Kobayashi Y; Soejima K; Satomi K; Furushima H; Ohe T; Ogawa S; Kodama I; Ohtsu H; Yamazaki T;
Circ J; 2006 Mar; 70(3):316-20. PubMed ID: 16501299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
